Géraldine Gebhart

1.7k total citations
26 papers, 980 citations indexed

About

Géraldine Gebhart is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Cancer Research. According to data from OpenAlex, Géraldine Gebhart has authored 26 papers receiving a total of 980 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Radiology, Nuclear Medicine and Imaging, 17 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Géraldine Gebhart's work include HER2/EGFR in Cancer Research (13 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Medical Imaging Techniques and Applications (10 papers). Géraldine Gebhart is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Medical Imaging Techniques and Applications (10 papers). Géraldine Gebhart collaborates with scholars based in Belgium, Italy and Netherlands. Géraldine Gebhart's co-authors include Martine Piccart, Zéna Wimana, Christos Sotiriou, Françoise Rothé, Barbara Lipert, Francis W. Hunter, Stephen M. F. Jamieson, Elisabeth G.E. de Vries, Patrick Flamen and Camilo Garcia and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Géraldine Gebhart

24 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Géraldine Gebhart Belgium 14 614 610 229 184 169 26 980
Joshua Z. Drago United States 9 742 1.2× 454 0.7× 255 1.1× 111 0.6× 356 2.1× 28 1.1k
Takashi Nakada Japan 7 1.1k 1.8× 677 1.1× 383 1.7× 82 0.4× 274 1.6× 14 1.3k
Federica Giugliano Italy 13 535 0.9× 271 0.4× 182 0.8× 135 0.7× 158 0.9× 32 708
Kathleen Tenner United States 13 658 1.1× 336 0.6× 113 0.5× 244 1.3× 185 1.1× 30 792
Yuki Abe Japan 10 892 1.5× 560 0.9× 296 1.3× 61 0.3× 281 1.7× 25 1.1k
Laetitia E. Lamberts Netherlands 13 473 0.8× 486 0.8× 181 0.8× 53 0.3× 127 0.8× 17 783
Yu-Waye Chu United States 5 992 1.6× 738 1.2× 133 0.6× 93 0.5× 204 1.2× 5 1.2k
Aya Sugyo Japan 19 311 0.5× 364 0.6× 198 0.9× 109 0.6× 272 1.6× 65 848
Eleonora Nicolò Italy 12 496 0.8× 222 0.4× 179 0.8× 149 0.8× 116 0.7× 39 635
Masako Soma Japan 4 689 1.1× 413 0.7× 251 1.1× 48 0.3× 159 0.9× 5 790

Countries citing papers authored by Géraldine Gebhart

Since Specialization
Citations

This map shows the geographic impact of Géraldine Gebhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Géraldine Gebhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Géraldine Gebhart more than expected).

Fields of papers citing papers by Géraldine Gebhart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Géraldine Gebhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Géraldine Gebhart. The network helps show where Géraldine Gebhart may publish in the future.

Co-authorship network of co-authors of Géraldine Gebhart

This figure shows the co-authorship network connecting the top 25 collaborators of Géraldine Gebhart. A scholar is included among the top collaborators of Géraldine Gebhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Géraldine Gebhart. Géraldine Gebhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marta, Guilherme Nader, et al.. (2025). PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial. European Journal of Nuclear Medicine and Molecular Imaging. 53(5). 3152–3161.
2.
Rediti, Mattia, Danai Fimereli, Zéna Wimana, et al.. (2024). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical Cancer Research. 31(1). 110–121. 3 indexed citations
3.
Vries, Elisabeth G.E. de, Thomas Guiot, Zéna Wimana, et al.. (2024). Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). npj Breast Cancer. 10(1). 4–4. 21 indexed citations
4.
Amato, Ottavia, Laurence Buisseret, Géraldine Gebhart, et al.. (2023). PIK3CAcopy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. Molecular Case Studies. 9(2). a006255–a006255. 5 indexed citations
5.
Agostinetto, Elisa, Carlo DeAngelis, P. Flamen, et al.. (2022). 230P Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study. Annals of Oncology. 33. S643–S643. 1 indexed citations
6.
7.
Gombos, Andrea, David Venet, Lieveke Ameye, et al.. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. npj Breast Cancer. 7(1). 125–125. 14 indexed citations
8.
9.
Cortés, Javier, Géraldine Gebhart, Manuel Ruíz Borrego, et al.. (2020). Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. Journal of Clinical Oncology. 38(15_suppl). 503–503. 15 indexed citations
10.
Hunter, Francis W., Barbara Lipert, Françoise Rothé, et al.. (2019). Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer. 122(5). 603–612. 213 indexed citations
11.
Lovinfosse, Pierre, Frédéric Goffin, Christine Gennigens, et al.. (2019). Added value of para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. European Journal of Surgical Oncology. 46(5). 883–887. 17 indexed citations
12.
Bartelink, Imke H., Ella F. Jones, Sheerin Shahidi-Latham, et al.. (2018). Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clinical Pharmacology & Therapeutics. 106(1). 148–163. 63 indexed citations
13.
Gingras, Isabelle, Géraldine Gebhart, Evandro de Azambuja, & Martine Piccart. (2017). HER2-positive breast cancer is lost in translation: time for patient-centered research. Nature Reviews Clinical Oncology. 14(11). 669–681. 57 indexed citations
14.
Wimana, Zéna, Géraldine Gebhart, Thomas Guiot, et al.. (2017). N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget. 8(34). 56185–56198. 13 indexed citations
15.
Gennari, Alessandra, Étienne Brain, Oriana Nanni, et al.. (2017). Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program. Annals of Oncology. 28. v31–v31. 7 indexed citations
16.
Gebhart, Géraldine, Patrick Flamen, Elisabeth G.E. de Vries, Komal Jhaveri, & Zéna Wimana. (2016). Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. Journal of Nuclear Medicine. 57(Supplement 1). 81S–88S. 40 indexed citations
17.
Gebhart, Géraldine, Laetitia E. Lamberts, Zéna Wimana, et al.. (2015). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology. 27(4). 619–624. 265 indexed citations
18.
Wimana, Zéna, Géraldine Gebhart, Thomas Guiot, et al.. (2015). Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model. Molecular Imaging and Biology. 17(5). 697–703. 11 indexed citations
19.
Gebhart, Géraldine, Cristina Gámez‐Cenzano, Eileen Holmes, et al.. (2013). 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. Journal of Nuclear Medicine. 54(11). 1862–1868. 104 indexed citations
20.
Garcia, Camilo, Géraldine Gebhart, & Patrick Flamen. (2012). New PET imaging agents in the management of solid cancers. Current Opinion in Oncology. 24(6). 748–755. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joshua Z. Drago Breakdown of academic impact, for papers by Takashi Nakada Breakdown of academic impact, for papers by Federica Giugliano Breakdown of academic impact, for papers by Kathleen Tenner Breakdown of academic impact, for papers by Yuki Abe Breakdown of academic impact, for papers by Laetitia E. Lamberts Breakdown of academic impact, for papers by Yu-Waye Chu Breakdown of academic impact, for papers by Aya Sugyo Breakdown of academic impact, for papers by Eleonora Nicolò Breakdown of academic impact, for papers by Masako Soma
Rankless by CCL
2026